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Public health arguments for collecting hemoglobin A1c (HbA1c) data, partic-
ularly in clinical settings, should be reframed to place more emphasis on
nonmedical determinants of population health. We compare individual- with
population-level interpretations of HbA1c titers. This comparison reveals that
public health researchers need to pay close attention to diagnostic tests and their
uses, including rhetorical uses. We also synthesize historical and current
evidence to map out 2 possible scenarios for the future. In the first scenario,
prevention efforts emphasize primary care and focus almost entirely down-
stream. The second scenario anticipates downstream interventions but also
upstream interventions targeting environments. Our analysis adapts actor–
network theory to strategic planning and forecasting in public health. (Am J
Public Health. 2012;102:99–106. doi:10.2105/AJPH.2011.300329)
In the past few years, prominent international
bodies have been agitating for hemoglobin
A1c (HbA1c) levels to become the criterion for
diagnosing type 2 diabetes mellitus. HbA1c is
a glycoprotein formed by a direct reaction
between blood glucose and hemoglobin.
HbA1c titers are significantly higher in pa-
tients with prolonged periods of hyperglyce-
mia. For this reason, HbA1c monitoring has
been used routinely for many years in clinical
research and in clinical practice to measure
diabetes control in patients. This protein is
present in all humans, and variation occurs
within and between populations. Indeed,
HbA1c has been used occasionally in social
epidemiology as a measure of population
health. How and the extent to which the
increased use of the HbA1c test to measure
individual health in clinical settings translates
into increased use of aggregated HbA1c re-
sults to measure population health will even-
tually have consequences for health policy,
resource allocation, and modes of interven-
tion. We have adapted actor---network theory
to explore the public health implications of
reorganizing type 2 diabetes diagnosis around
HbA1c assays. In particular, we examined how
HbA1c levels in patients and populations
are being used to promote particular views
about physiology and behavior, without
discussion of the potential significance of
HbA1c data as a measure of population health
and an indicator of upstream causes of mor-
bidity and mortality.
The move toward HbA1c-based diagnosis
has generated controversy.1 Proponents have
offered several justifications for this substantial
shift in clinical practice: (1) the failure of
current diagnostic standards to halt the pro-
gression of secondary macrovascular disease,
(2) the stability of the HbA1c molecule as
a measure of average blood glucose levels
over a period of weeks, and (3) an increasing
trust in the reliability of HbA1c measure-
ments.2,3 Proponents believe the HbA1c test has
tremendous potential to identify prediabetic in-
dividuals before the onset of irreversible dam-
age.4 Yet changing the criteria by which type 2
diabetes is diagnosed is not only a move to
prevent the onset of disease and disability.
Knowledge about the properties and significance
of the HbA1c molecule is framed by other
information about at-risk individuals, early tar-
geted treatments, and comparable diabetic and
nondiabetic populations.5 Changing the way
prediabetic individuals are identified and classi-
fied will likely reorient the way patients, care
providers, and institutions understand and re-
spond to the escalating incidence and risks of
diabetes in many different populations.6
STRESSORS AND SOCIAL
ENVIRONMENTS
Stressors (i.e., negative events, chronic
strains, and traumas) have consistently been
shown to negatively affect human health across
the life span when measured comprehensively
and cumulatively.7,8 Furthermore, a key way
that gender, race/ethnicity, and socioeconomic
disparities contribute to health inequalities ap-
pears to be through differential environmental
exposure to stressors.7,8 The social dimensions of
an environment influence health not only by
influencing behavior, but also by mechanisms
that are still poorly understood.
Nevertheless, long-running debate has fo-
cused on the extent to which popular notions
and some scientific operationalizations of
stress reflect middle-class, adult, and male
experiences.9,10 Reviews of research involving
animals, in both laboratory and field settings,
temper such critiques. Animal studies provide
support for the view that negative experiences
affect biological processes and are associated
with poorer health across the life span.8,11 The
importance of bonding and supportive relation-
ships for resiliency is also suggested by animal
studies.8,10 Although many questions remain
about the significance of stressors for the health
of human populations, current conceptions re-
volve around a social gradient of disease. Re-
searchers posit that biological responses to
stressors, which arise to varying degrees in dif-
ferent social environments, ultimately influence
health outcomes.8,12,13
Because HbA1c provides an index of a per-
son’s exposure to hyperglycemia, and because
glycemic levels are implicated in the biological
response to stressors, social epidemiologists
have turned to HbA1c as a potential biological
marker of exposure to stressors in different
social environments.13,14 Studies of HbA1c
found that modest increases in the level of this
glycoprotein correlated with psychological
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measures of job stress,15,16 increased risk of heart
disease in men,17 and other chronic morbidities
in nondiabetic populations.18--20 Although the
mechanisms are not well characterized, an in-
dependent and inverse association with HbA1c
levels was associated with employment grade in
the Whitehall Study.21 A large body of cross-
sectional data held by the National Health and
Nutrition Examination Survey in the United
States showed that HbA1c levels were signifi-
cantly associated with key measures of socio-
economic status and stress in both men and
women.22 Nevertheless, important limitations
still exist in knowledge about HbA1c, stressors,
social environments, and the health of human
populations. One important concern is that the
existing research evidence is almost entirely
derived from cross-sectional studies.
The use of a biological measure such as
HbA1c to assess relative health and exposure
to stressors in different populations has im-
portant implications in health policy formation
and the allocation of scarce resources. It is
increasingly clear that human behavior and
individual genetic inheritance account for only
some of the individual variation in health
status; biological measures such as HbA1c
levels might therefore usefully serve as a means
to identify and monitor populations at risk of
increased burdens of disease.13,14 In the aggre-
gate, databases containing HbA1c measures
could be used in research on stressors, social
environments, and the health of human popula-
tions. For example, a research group recently
used HbA1c measures in an administrative
database in a cross-sectional study of whether
neighborhood characteristics were associated
with type 2 diabetes control. Black veterans who
had been previously diagnosed with type 2
diabetes and who lived in neighborhoods with
high scores on a ‘‘working together to improve
the neighborhood’’ survey item tended to have
lower HbA1c levels.23(p519)
More research on links between stressors,
social environments, and HbA1c levels is war-
ranted, but it will heavily depend on the in-
clusion of HbA1c measures in surveys and in
administrative databases. Should HbA1c levels
become a routine screening and diagnostic tool
for type 2 diabetes, the potential value of
administrative databases in social epidemiol-
ogy and intervention research would expand.
Such data sets would contain information on
more people over longer periods, and the
impact on HbA1c levels from, for example,
community interventions to increase social
cohesion, could be studied. Large administra-
tive databases with longitudinal HbA1c data
could assist in moving beyond the limitations of
cross-sectional studies in providing research
evidence for translation into policy and pro-
gramming initiatives.
HEMOGLOBIN A1C AND TYPE 2
DIABETES MELLITUS
Although the apparent association between
social stress and HbA1c is of increasing interest
to population health researchers, elevations
in this glycoprotein also occur in individuals
with diabetes, of which the most prevalent form
is type 2. This condition is characterized by
hyperglycemia and disturbed lipid, protein, and
carbohydrate metabolism. Unlike type 1 di-
abetes, type 2 is considered to be preventable.
Because high blood glucose is the metabolic
hallmark of a diabetic state, past efforts to
identify the condition have focused on glucose
determination––usually through a standardized
protocol of blood glucose measurements.24
The validation of the HbA1c test in diabetes-
related discourse is a relatively recent event.25
Endocrinologists and pharmaceutical companies
were looking for a new hyperglycemic bio-
marker to track during drug safety and efficacy
evaluations in the 1970s. The HbA1c glycopro-
tein was attractive because it reliably indexes the
level of blood glucose in an individual over 6
weeks, unlike snapshot glucose measurements.
In the 1990s, the 2 most influential large-
scale clinical trials of diabetic therapeutic regi-
mens––the Diabetes Control and Complications
Trial and the United Kingdom Prospective
Diabetes Study––established changes in the
titer of HbA1c molecules as an effective means
to monitor glucose control in individual di-
abetic patients.26,27 These studies promoted
wholesale changes in the treatment of diabetic
patients because they also confirmed that the
HbA1c glycoprotein is a reliable index of the risk
of both microvascular and macrovascular com-
plications. Many health care providers changed
their clinical routines in response to these find-
ings. They continued to definitively diagnose
diabetic individuals through snapshot blood
glucose determinations, but they began to use
HbA1c rather than fasting plasma glucose levels
to monitor diabetes control and plan treatments.
HbA1c has thus become a crucial tool for health
professionals to measure and address the ad-
herence of individuals to prescribed therapies
(diet, exercise, and medication),25,28 as well as to
prescribe additional therapies, notably medica-
tion. People with diabetes are advised to strive
for diabetes control, partly by regularly measur-
ing plasma glucose values (i.e., self-managed
blood glucose monitoring), but also through
vigilance about eating and exercising. This em-
phasis on self-control predates the use of HbA1c
in diabetes treatment; the widespread adoption
of HbA1c as a measure of diabetic control
reinforced and amplified a familiar way of
thinking, by means of a novel technology.29,30
Yet the practice of attaining tight glucose
control through self-monitoring is slowly falling
out of favor. In follow-up studies, aggressive
glucose-specific measures have been found to
be inadequate for achieving the stated goals of
reducing the incidence of macrovascular fatal-
ities in people diagnosed with type 2 diabe-
tes.31,32 Although these results are contested, the
weight of opinion is that disciplined glucose
regulation is insufficient to halt the development
of diabetic complications. When the diagnosis
of type 2 diabetes is delayed– no matter how
tight the subsequent glucose control– onset of
other chronic diseases seems to be inevitable.
Because existing systems of diagnosis fail to
detect a significant proportion of people who
subsequently develop type 2 diabetes, many
diabetologists now believe that earlier interven-
tion is necessary. Because diabetes onset is subtle
and gradual––and it is often difficult to pinpoint
when someone with type 2 diabetes has truly
become a diabetic– a concerted effort is being
mounted to base diabetes diagnosis as well as
diabetes treatment on HbA1c measurement.
Because HbA1c accurately predicts both micro-
vascular and macrovascular disease, proponents
propose that an HbA1c blood level greater
than 6.5 millimoles per liter should become
the diagnostic gold standard for all forms of
diabetes2--4 and that 6 millimoles per liter be
accepted provisionally as a positive screen for
type 2.2,33,34
Clearly, the evidentiary basis of type 2
diabetes diagnosis, care, and prevention is in
transition. Many authors have noted that
changes in how medical evidence, such as
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diagnostic tests, epidemiological databases, and
clinical trials, is produced and appraised can
have many and varied political, personal, and
structural effects.35,36 Not all of these are
anticipated by the proponents of change. At-
tempts to standardize clinical practice around the
best available evidence may not only direct
individual treatments but also mandate changes
in public policy and agreed-upon evidentiary
forms, thereby reformulating the legitimacy of
claims to authority.37
ACTOR–NETWORK INSIGHTS
Our analysis of potential public health im-
plications of changing the evidentiary status of
HbA1c and recommendations is informed by
scholarship in the interdisciplinary field of
science and technology studies. Actor---network
theory is a theoretical resource that provides
a comprehensive and empirically grounded
framework for understanding innovations
within systems. Actor---network scholarship
has generated important insights about links as
well as gaps between clinical practice, epide-
miological research, and programs within and
outside the health care sector that can influence
health and disease in entire populations.38,39
Nevertheless, this scholarship has yet to be
applied extensively in public health.40--42
Actor---network theorists emphasize that
ideas and things, the semiotic and material
elements that compose any system, inevitably
and continually shape one another. Research
informed by this theoretical tradition has,
for example, highlighted that physical dimen-
sions of environments, such as automobiles and
traffic patterns, are socially mediated and
entwined with the history of medicine in un-
expected ways.43 As expertly demonstrated
by Young et al. in their analysis, informed by
actor---network theory, of the history of smoke-
free public spaces,41 when ideas and things are
part of highly complex systems, they are typically
limited by a repertoire of established responses.
Changing the evidentiary status of HbA1c from
a useful measure of control and risk to a di-
agnostic criterion and screening technology is
therefore a significant step that will reshape the
network of concepts, values, practices, and actors
that drives efforts to prevent, diagnose, and
effectively treat type 2 diabetes. Young et al.
illustrate in a diagram how an established
network responds to fundamental change and
reform where heterogeneous elements (links and
knots) such as people, research evidence, tech-
nologies, and financial resources interact and
consolidate to realize a goal––such as diabetes
prevention––that in turn ends up restructuring
many aspects of everyday reality (Figure 1).
Representing the relationships between
people, institutions, technologies, and evidence
through an actor---network approach illumi-
nates how problems emerge in a system and
how a system is reshuffled in response to bring
about a solution. Young et al. describe 4 loops
that reach out from a central reorganizing
network (Figure 1) and that
represent activities designed to link the core with
4 interdependent sources of power: scientific
evidence and the technologies or techniques that
depend on it, professional or political authority,
allies, and public opinion.41(p1209)
These loops then provide the means for net-
work stabilization, such as the mobilization
of science, technology, and theory to frame
the issue; alliance building to solidify and
defend the new network vis-à-vis alternative
concepts and technologies; processes and in-
terests that shape the social acceptance of
the new system; and institutionalization or
authoritative systematic acceptance of the
new equilibrium. These loops or steps do not
necessarily occur in sequence, nor are they
determined by the weight of verified evi-
dence. The institutionalization and social ac-
ceptance of the new system equilibrium is
shaped, at least in part, by the relative success
of the innovators in marshaling resources,
evidence, and allies to support and manage
the new network.
CURRENT SITUATION
Because diagnostic tests also provide the
underlying structure to diagnostic categories,
test results propel patients down systematized
clinical pathways and into new social groups
and, potentially, motivate them and their close
kin to reorient themselves within a new way
of living.30,44 Diagnostic tests give biomarkers,
cell lines, genes, infectious agents, and other
entities their prognostic and social significance.
Changing what is perceived as the definitive test
for a specific condition, therefore, can ultimately
change disease definitions and classifications
and, indeed, patient identity, social support, and
Source. Young et al.41(p1297)
FIGURE 1—Innovations in systems according to actor–network theory.
FRAMING HEALTH MATTERS
January 2012, Vol 102, No. 1 | American Journal of Public Health Degeling and Rock | Peer Reviewed | Framing Health Matters | 101
status. Past studies indicated that the choice of
diagnostic criterion for diabetes is also implic-
itly a choice of which particular phenomenon
associated with the disease––sugar or glyco-
protein, patient or population––will be the
central articulation around which efforts will
be made to characterize, identify, and manage
its effects.6,29
Adapting the Young et al. actor---network
analysis of evidence-based innovation41 to the
current debate about using HbA1c to screen for
and to diagnose type 2 diabetes shows how the
accumulation of epidemiological data can
translate into treating type 2 diabetes as
a pressing social and public health problem in
clinical settings and in primary care policy-
making (Figure 2). These loops represent 4 key
processes: (1) HbA1c assays and population
health data are being mobilized to establish the
harms associated with chronic hyperglycemia;
(2) alliances are being formed and repositioned
between professional groups to organize a co-
ordinated response to the growing signi-
ficance of current and future burdens of
chronic diseases, notably type 2 diabetes,
microvascular disease, and macrovascular
disease; (3) institutionalization is occurring
as more actors accept the significance of the
HbA1c molecule as evidence of populations
at elevated risk for cardiometabolic disease
and as an index of health risks for individuals;
and (4) expert opinion is beginning to cohere
around a perceived need to use HbA1c data
to respond to the social implications and
future disease burdens associated with higher
rates of type 2 diabetes in healthy, at-risk,
and clinically treated populations, and such
an approach appears to be socially accept-
able. Once the importance of this issue is
established, the problem facing all those
in the network is deciding on the most
appropriate response: the best target and the




Of increasing importance is whether to
continue to direct almost all available resources
toward individual cases or to invest in inter-
ventions targeting entire populations as well. A
focus on individual cases emphasizes down-
stream, or proximal, causes, particularly indi-
vidual behavior (following recommendations
for diet, exercise, and medication); a focus on
populations emphasizes upstream, environ-
mental causes. The likely consequences of both
strategies for the US health care system were
simulated by Jones et al. at the National Center
for Chronic Disease Prevention, Centers for
Disease Control and Prevention, and were
published in this journal.45 Their complex
population dynamics model predicts that a
mixture of individual- and population-focused
measures that address type 2 diabetes as a het-
erogeneous system is the most appropriate long-
term strategy.
The use of actor---network scholarship in
formulating policy prescriptions with the in-
tent of promoting a favored outcome has
faced long-standing resistance.46,47 Nonethe-
less, tentative steps are being taken toward
drawing on actor---network scholarship to map
out the implications of current events and, more
significantly, provide action-oriented evi-
dence.48,49
We do not oppose the use of HbA1c data to
manage type 2 diabetes or to identify pre-
diabetic individuals. The advantages of reor-
ganizing clinical practices around the blood
level of this molecule are compelling. The
HbA1c test represents the level of blood glu-
cose over months rather than minutes and
provides an index to determine differences
in morbid risks between patients. It produces
a continuum from the hyperglycemic past
to future health, replacing freeze-frame diag-
nosis and surveillance. Because the HbA1c
test is thought to have greater sensitivity for
marginally hyperglycemic individuals, and
therefore identifies a larger cohort of patients
who have the early subclinical stages of poor
Note. GBT = glucose-based test; HbA1c = hemoglobin A1c; PHA = population health assessments; S&PE = social and physical
environments; T2DM = type 2 diabetes mellitus.
FIGURE 2—Network mapping the rising prominence of HbA1c data and the coemergence of
type 2 diabetes mellitus complications as a pressing public health issue.
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glucose regulation, it is possible that over
time, diabetes––like hypertension and high
cholesterol––will be mainly perceived as a risk
factor for other chronic diseases and premature
death. As evidence of the cardiovascular im-
pact of this metabolic problem mounts,20,50
momentum within this new network is building
around the notion that ‘‘the comprehensive
care of diabetes involves the treatment of all
vascular risk factors––not just hyperglycae-
mia.’’51(p355)
Exposure to stressors in social environments
are known to have adverse health effects;
therefore, steps that promote the reduction of
disparities within and between populations––
such as facilitating healthy diets, regular exer-
cise, and safer neighborhoods––could have
a profound impact on diabetes incidence,
HbA1c levels, and associated human suffer-
ing.45,52 The current situation (Figure 2) could
evolve such that stressors, which vary across
environments and which seem to influence
HbA1c in populations, remain overlooked and
consequently ignored.
TWO POSSIBLE FUTURES AND THEIR
PUBLIC HEALTH IMPLICATIONS
In much the same way as Jones et al.
compared the future consequences of indi-
vidual versus mixed type 2 diabetes inter-
vention strategies,45 we anticipated 2 future
configurations by applying an adaptation of
actor---network theory prospectively to the cur-
rent focus on reducing the burdens of diabetes
complications through self-management and
clinical interventions hinging on HbA1c (Figure
2). Both scenarios presume that HbA1c would
be used to screen for and diagnose type 2
diabetes, but aggregated HbA1c data would be
mobilized in distinct ways. In the first scenario,
the focus would remain almost entirely on
primary care and individual self-management,
with a view to averting or at least delaying the
downstream consequences of type 2 diabetes
mellitus (Figure 3). In the second scenario, a focus
on overall population health and upstream inter-
ventions would parallel treatment efforts (Figure 4).
In our first projected network (Figure 3), the
evidentiary significance of HbA1c data would
become completely enmeshed with the con-
cerns of primary care. As a consequence,
HbA1c titers would only be construed as
a measure of lifestyle risks, diabetic control,
and quality of individuals’ treatment. The
potential relevance of HbA1c measurements to
population health as a tool to monitor and
better target population-level interventions
would be subsumed by efforts to identify and
ameliorate type 2 diabetes in particular people
before they head further downstream.
DOWNSTREAM AND UPSTREAM
INTERVENTIONS FOR OBESITY
Evidence suggests that interventions focused
on weight loss––whether through lifestyle
changes, new medications, or bariatric sur-
gery––are the most effective early treatment
and preventive measures for type 2 diabe-
tes.53,54 Although the rising incidence of weight-
related health problems in many populations
worldwide stems, in all likelihood, from the
interplay of social, cultural, demographic, and
economic trends, intervention research to ad-
dress the root causes has not found much favor
among diabetes experts.55,56 When issues re-
lating to the increasing incidence of health
risks in populations are framed alongside the
positive attributes of the HbA1c test, professional
opinion leaders are comfortable claiming that
now is the time to evaluate ‘‘the public health,
economic and practical implications of redefining
the diagnostic criteria for diabetes.’’4(p2247)
However, despite the acknowledgment that di-
abetes is a public health issue related to in-
teractions between food, activity levels, and
environment, the HbA1c test is being used stra-
tegically to frame this population-wide problem
as amenable to clinical management and, ulti-
mately, self-management through adherence
to professional advice regarding diet, exercise,
and medication.2
Some practitioners and researchers, looking
beyond the scientific evidence, also hope that
Note. BoD = burden of disease; HbA1c = hemoglobin A1c; Intx = interventions; T2DM = type 2 diabetes mellitus.
FIGURE 3—Prospective network with HbA1c data used only in primary care to prevent type 2
diabetes mellitus and related complications.
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deploying HbA1c as a diagnostic screen will
have an explicit rhetorical impact, drawing the
focus of people, their caregivers, regulators,
and planners to preventive actions.34,57 Yet
despite the evident potential for a broader public
health focus, high HbA1c levels in distinct groups
of people are not stimulating recognition of the
need for population-level interventions. Instead,
the HbA1c test is only being used as an explicit
link between asymptomatic states in individuals
and their risk of future disease, thereby permit-
ting earlier interventions and a coherent flow
of clinically mediated actions and future evalua-
tions. With the widespread adoption of HbA1c-
based diagnosis, it is likely that a larger pro-
portion of the population will find themselves
among the ranks of prediabetic patients who
are encouraged to regulate their lives and life-
styles––as individuals.58 The success of these
activities––and patients’ adherence––will be
measured against their HbA1c levels, if current
trends continue, under the direct supervision
of primary health care providers.
HbA1c entered mainstream diabetic dis-
course through pharmaceutical trials and not
through social epidemiology or population
health interventions. Although it is not con-
strued this way, the HbA1c test offers not only
a record of patients’ hyperglycemia and be-
havioral history, but also a précis of their
exposure to stressors. Although the promotion
of the HbA1c test implicitly acknowledges that
conditions that promote hyperglycemia are
widespread, the link between elevated levels of
this molecule and different populations’ envi-
ronments remains underemphasized. At this
time, the HbA1c test is only being promoted as
a means to enable population-level change
through small increments in individuals, often
to be achieved only by resisting trends in
physical and social environments.58 It is argu-
able that when positioned alongside the current
emphasis on weight and the health risks of
obesity, the HbA1c test is being deployed as
a rhetorical resource to try to monitor and
intervene in the individual lives and lifestyles
of a larger proportion of the population. This
approach ignores the potential for improving
population health through primary prevention
via interventions in sectors other than health





Other configurations of knowledge and
practice are possible. For example, HbA1c data
collected in the course of identifying and
treating individual patients with type 2 diabetes
can also tell us about the average levels of
HbA1c in distinct populations. Secondary
analysis could create further evidence that
could encourage population-based interven-
tions for obesity and other socially mediated
health risks and diseases. As Young et al. point
out, the credibility of this alternative network of
evidence, theories, and values depends not
only on its internal coherence, but also on its
generalizability and ability to engage diverse
sectors.41
As diabetes and its morbid complications are
increasingly recognized to be a pressing and
significant population health problem, the col-
lation of HbA1c data as a measure of the
diabetic risk of specific populations could
highlight––and possibly reverse––the lack of
attention to upstream causes of this condition.
In our second prospective network, HbA1c
titers would be not only a measure of the
health, diabetic risks, and self-management by
individuals, but also an index of underlying
health disparities and a means to identify and
monitor populations at risk of increased bur-
dens of disease. Alliances between planners
and population health researchers could
broaden the agenda to gain public support for
and ultimately institutionalize alternative
modes of intervention focusing on physical and
social dimensions of environments.
If epidemiological data from population-
based testing is to be used to better manage
morbid risks in individual patients, we need to
pay closer attention to technologies of primary
Note. HbA1c = hemoglobin A1c; PH = population health; S&PE = social and physical environments; T2DM = type 2 diabetes
mellitus.
FIGURE 4—Alternative network after mobilization of HbA1c as a resource for primary care
and for promoting the physical and mental health of populations.
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care. When clinicians use a test during diag-
nostic determinations, the audiences––patients,
their caregivers, and health professionals––are
being furnished with a set of perspectives,
interpretations, and explanations. In turn, the
results of diagnostic tests populate databases
and can inform the formulation and imple-
mentation of policies of many different kinds
and in many different settings. In each cir-
cumstance, what is being communicated is
not just a set of facts or a causal story that can
be fitted into an archetypical illness script or
the likely prognosis. What is being trans-
ferred or translated also includes a disciplin-
ary perspective and its supporting socio-
technical network––in essence, a way of
knowing.59,60
If nothing else, the potential use of HbA1c to
represent and index the relative health and
well-being of populations––rather than healthy,
diseased, or at-risk individuals only––could
assist in the future prevention and manage-
ment of type 2 diabetes and many other
chronic health problems. As illustrated by
Figure 4, it is conceivable that HbA1c admin-
istrative data could be mobilized through re-
search to assess the impact of different envi-
ronments. Current practice, however, is
indicative of how we are attempting to deal
with weight-related dysfunctions without ex-
plicitly addressing the health inequities pro-
duced by obesogenic and stressful environ-
ments.18,56,61
CONCLUSIONS
The distribution of HbA1c in individuals and
in populations is being proposed to serve as
a resource that substantiates specific clinical
practices. This is a narrow perspective that
ignores many plausible venues for intervention
outside health care to address the burgeoning
prevalence of type 2 diabetes and related
health problems. International advisory bodies
and expert consensus groups are using epide-
miological data and improved levels of stan-
dardization across diagnostic laboratories to
bolster arguments for a change in diagnostic
criteria.62 The impetus behind retooling HbA1c
level as the diagnostic criterion for type 2 di-
abetes is to address ‘‘individuals within the
collective’’ without acknowledgement of the
health gains that could stem from recognizing
the existence of ‘‘collectives of interacting indi-
viduals.’’63(p242)
The journey of the HbA1c test toward
becoming the accepted diagnostic tool for type
2 diabetes highlights why public health re-
searchers need to pay close attention to di-
agnostic tests and their uses, including rhetor-
ical uses. We see a need to reframe public
health arguments for collecting HBA1c data, in
clinical as well as nonclinical settings, to place
more emphasis on the determinants of popu-
lation health and on population health inter-
vention research. j
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